Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Official Title
-----------------
Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Conditions
-----------------
INFERTILITY, Fertility Preservation, Ovulation Induction, Vitrification, Oocyte Donation

Intervention / Treatment
-----------------
* Drug: gonadotropins plus GnRH antagonists
* Drug: ganirelix


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: premenopausal women, 18-35 years old, FSH levels < 10 mIU/ml; AFC> 10 regular cycles BMI < 28 signed informed consent Recipients: Infertile women eligible for oocytes donation BMI < 35 Signed informed consent form Exclusion Criteria: -Polycystic ovarian syndrome, gonadotropins allergy Recipients: Women eligible for oocytes donation BMI >35 Uncontrolled Endocrine Pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lutheal phase ovarian stimulation<br>Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage. | Drug: gonadotropins plus GnRH antagonists<br> <br> * Other names: Ovarian stimulation;Drug: ganirelix<br> <br> * Other names: the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate |  | six weeks after transfer procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Mature oocytes |  | Day of oocyte retrieval | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian stimulation, Luteal phase, Egg donors, Fertility preservation